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The MYC oncogenic transcription factor is a 
key regulator of cell growth and proliferation 
that plays a central role in the pathogenesis of   
a wide range of human cancers (Pelengaris and 
Khan, 2003). In T cell acute lymphoblastic leu-
kemia (T-ALL), MYC is typically overexpressed 
downstream of activated NOTCH1 (Palomero 
et al., 2006; Sharma et al., 2006; Weng et al., 
2006). In most experimental models of MYC-
induced tumorigenesis, ongoing MYC activity 
is required for tumor maintenance, and MYC 
down-regulation results in loss of the malignant 
phenotype  via  apoptosis  or  differentiation/ 
senescence (Arvanitis and Felsher, 2006). Indeed, 
experimental evidence indicates that a subset of 
human T-ALL cell lines is dependent on aber-
rant MYC overexpression (Weng et al., 2006). 
Although Myc is required for normal cellular 
proliferation and development (Davis et al., 1993; 
Trumpp et al., 2001), recent work has demon-
strated that the widespread inhibition of Myc, 
by expression of a dominant-interfering basic 
helix-loop-helix leucine zipper domain, is sur-
prisingly well tolerated and induces regression 
of Ras-induced lung tumors (Soucek et al., 2008). 
These findings, together with advances in ther-
apeutic  targeting  of  protein–protein  interac-
tions, have rekindled interest in the development 
of clinically useful strategies for MYC inhibi-
tion (Verdine and Walensky, 2007; Prochownik 
and Vogt, 2010). Thus, elucidating the deter-
minants of a tumor cell’s response to MYC 
inhibition could have important therapeutic 
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The MYC oncogenic transcription factor is overexpressed in most human cases of T cell 
acute lymphoblastic leukemia (T-ALL), often downstream of mutational NOTCH1 activation. 
Genetic alterations in the PTEN–PI3K–AKT pathway are also common in T-ALL. We gener-
ated a conditional zebrafish model of T-ALL in which 4-hydroxytamoxifen (4HT) treatment 
induces MYC activation and disease, and withdrawal of 4HT results in T-ALL apoptosis and 
tumor regression. However, we found that loss-of-function mutations in zebrafish pten 
genes, or expression of a constitutively active Akt2 transgene, rendered tumors indepen-
dent of the MYC oncogene and promoted disease progression after 4HT withdrawal.  
Moreover, MYC suppresses pten mRNA levels, suggesting that Akt pathway activation 
downstream of MYC promotes tumor progression. Our findings indicate that Akt pathway 
activation is sufficient for tumor maintenance in this model, even after loss of survival 
signals driven by the MYC oncogene.
© 2011 Gutierrez et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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(Langenau et al., 2003, 2005a). To generate a zebrafish model 
of T-ALL in which MYC activity could be modulated in 
established tumor cells, we generated stable transgenic zebrafish 
expressing rag2:MYC-ER, in which the zebrafish rag2 pro-
moter drives expression of a fusion transgene consisting of 
human MYC fused to the ligand-binding domain of a modified 
consequences. Several tumor cell–intrinsic genetic determi-
nants of Myc oncogene dependence have been identified, 
including p16INK4a, Rb, and p53 (Wu et al., 2007), as   
well as an autocrine signaling pathway mediated by TGF-  
(van  Riggelen  et  al.,  2010).  Moreover,  host-dependent 
mechanisms have also been implicated in tumor regression 
after Myc inactivation, involving inhibition of angiogenesis 
(Giuriato et al., 2006; Sodir et al., 2011) and the cellular im-
mune system (Rakhra et al., 2010).
The  PI3K–AKT  signal  transduction  pathway,  which  is 
negatively regulated by the PTEN tumor suppressor, mediates 
oncogenic signaling downstream of growth factor receptors and 
is frequently dysregulated in human cancer (Chalhoub and 
Baker, 2009). We have recently identified genetic alterations 
within the PTEN–PI3K–AKT pathway in 48% of primary 
T-ALL patient samples (Gutierrez et al., 2009), clearly impli-
cating this pathway in human T-ALL pathogenesis. Constitu-
tive signaling though the PI3K–AKT pathway in T-ALL has 
been implicated in resistance to NOTCH1 inhibitors (Palomero 
et al., 2007), which are effective in part as a result of their down-
stream effect on MYC expression (Palomero et al., 2006; 
Sharma et al., 2006; Weng et al., 2006). In a mouse model of 
MYC-induced mammary tumorigenesis, loss of MYC de-
pendence was strongly associated with the acquisition of acti-
vating mutations in Kras2 (D’Cruz et al., 2001), suggesting 
that activation of signal transduction pathways downstream of 
RAS, such as the PI3K–AKT pathway, can overcome depen-
dence on MYC. Moreover, MYC has recently been shown to 
promote signaling through the PI3K–AKT pathway via up-
regulation  of  micro-RNAs  that  down-regulate  PTEN  
(Mu et al., 2009; Olive et al., 2009; Kim et al., 2010; Mavrakis 
et al., 2010). Consistent with these findings, Myc inactivation 
was followed by transcriptional up-regulation of Pten in mouse 
Myc-dependent osteosarcomas (Wu et al., 2008). However, 
the hypothesis that the PTEN–PI3K–AKT pathway mediates 
Myc dependence has not previously been tested, as previous 
efforts to overexpress Myc in Pten-null mouse pancreatic  
cells led to massive apoptosis without tumor development 
(Radziszewska et al., 2009).
In this manuscript, we used a conditional zebrafish model 
of  MYC-induced T-ALL  to  test  the  hypothesis  that AKT 
pathway activation can substitute for MYC signals required 
for tumor maintenance in vivo. We found that loss-of-function 
pten mutations or constitutive Akt activation were strongly asso-
ciated with loss of MYC oncogene dependence, suggesting 
that PI3K–AKT pathway activation can functionally replace 
signals mediated by an activated MYC transgene in the main-
tenance of T-ALL transformation.
RESULTS
Conditional T-ALL development in rag2:MYC-ER  
transgenic zebrafish
We previously generated a zebrafish model of T-ALL, using 
rag2 promoter-driven expression of a mouse EGFP-Myc 
fusion transgene to induce T-ALL which closely resembles 
the  human  disease  pathologically  and  by  gene  expression 
Figure 1.  Conditional T-ALL development in rag2:MYC-ER trans-
genic zebrafish. (A and B) Thymic fluorescence in control MYC-ER– 
negative lck-EGFP transgenic (A) and rag2:dsRed2 transgenic (B) zebrafish 
raised in the absence of 4HT. (C and D) Thymic fluorescence in the  
absence of 4HT treatment in rag2:MYC-ER transgenic zebrafish that also 
expressed lck-EGFP (C) or rag2:dsRed2 (D). For A–D, one representative 
zebrafish is shown from a minimum of eight fish raised in each condition. 
(E and F) Fully penetrant T-ALL in rag2:MYC-ER transgenic zebrafish raised 
in 50 µg/liter (129 nM) 4HT. A representative triple-transgenic rag2:MYC-
ER; lck:EGFP; rag2:dsRed2 zebrafish is shown at the time of disseminated 
T-ALL development, imaged in both green and red fluorescent channels. 
(G and H) Thymic fluorescence in the rag2:MYC-ER transgenic zebrafish 
from E and F, shown 4 wk after 4HT removal. In all triple-transgenic 
zebrafish in which regression occurred (n = 6 of 8), T-ALL regression  
occurred simultaneously in both green and red fluorescent channels, with 
no evidence of residual EGFP-positive dsRed2-negative mature T cells, 
indicating that differentiation was not the primary mechanism of T-ALL 
regression. Bar, 1 mm. (I) After T-ALL development, zebrafish were either 
removed from 4HT to down-regulate the MYC transgene (4HT) or kept 
in 4HT (+4HT), and tumor phenotype was assessed 8 wk after 4HT re-
moval. Zebrafish that became moribund with leukemia before the 8-wk 
time point were euthanized and classified into the progression category. 
Number of fish analyzed per condition: 4HT, n = 8; +4HT, n = 13.JEM Vol. 208, No. 8 
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dsRed2-negative mature T cells (Fig. 1, E–H). Furthermore, 
examination of the senescence marker acidic -galactosidase 
activity revealed no increase above background levels in T-ALL 
cells after MYC inactivation (Fig. S2). In some settings, col-
lapse of the tumor-associated vasculature is involved in tumor 
regression after MYC inactivation (Giuriato et al., 2006; Sodir 
et al., 2011); thus, we also examined whether MYC inactiva-
tion affected the tumor vasculature, taking advantage of fli1:
EGFP transgenic zebrafish in which EGFP is robustly ex-
pressed in vascular endothelium (Lawson and Weinstein, 2002). 
Immunohistochemistry for EGFP in rag2:MYC-ER;rag2:
dsRed2;fli1:EGFP triple-transgenic zebrafish revealed no sig-
nificant differences in tumor-associated microvascular density 
4 d after MYC inactivation (Fig. S3).
Immunohistochemical analysis of T-ALL cells from rag2:
MYC-ER transgenic zebrafish revealed increased staining for 
the apoptotic marker activated caspase 3 after removal from 4HT 
(Fig. 2 A), implicating the induction of apoptotic cell death in 
T-ALL cells after MYC down-regulation. We thus reasoned 
estrogen  receptor  that  is  posttranslationally  induced  by   
4-hydroxytamoxifen (4HT) treatment but not by endogenous 
estrogens (Littlewood et al., 1995). When treated with vehicle 
control (ethanol), rag2:MYC-ER heterozygous fish did not 
develop T-ALL over a 16-wk follow-up period. Thymic 
fluorescence in 8-wk-old rag2:MYC-ER transgenic fish co-
expressing lck:EGFP and rag2:dsRed2 transgenes that were 
treated with vehicle control was indistinguishable from that of 
their rag2:MYC-ER negative siblings (Fig. 1, A–D). However, 
when MYC-ER was induced by treatment with 50 µg/liter 
(129 nM) 4HT beginning at 5 d postfertilization, rag2:MYC-
ER  transgenic  zebrafish  developed  fully  penetrant T-ALL 
starting at 5 wk of age (Fig. 1, E and F). Histological analysis 
of T-ALL tumors induced by rag2:MYC-ER alone revealed 
that these tumors consisted of sheets of monomorphic lym-
phoblasts characterized by regular nuclear contours, scant cyto-
plasm, homogeneous chromatin, and inconspicuous nucleoli 
(Fig. S1), morphological features which closely resemble those 
of human T-ALL lymphoblasts. Note that no phenotypic dif-
ferences were observed between these tumor cells and those 
arising in zebrafish of other genotypes studied throughout 
this manuscript (Fig. S1).
To test whether these tumors were dependent on ongoing 
MYC  transgene  activation,  zebrafish  with T-ALL  were   
removed from 4HT to down-regulate MYC activity, and 
tumors were monitored weekly for 8 wk by fluorescence im-
aging. Tumor phenotypes were then classified into four cate-
gories based on the degree of change in tumor size by the end 
of  the  8-wk  monitoring  period:  (1)  complete  regression 
(disappearance of all abnormal extrathymic fluorescence), 
(2) partial regression (reduction in tumor diameter to less than 
half its original size), (3) stable disease (tumors that did not 
meet criteria for regression or progression), and (4) progres-
sion (increase in tumor diameter to more than twice its 
original size). After T-ALL development, removal from 4HT 
induced complete tumor regression in 75% of zebrafish ex-
amined, whereas tumor regression was not seen in any of the 
zebrafish kept in 4HT (Fig. 1 I; P = 0.0001).
MYC down-regulation induces mitochondrial apoptosis  
in T lymphoblasts
In most experimental models of MYC-induced tumori-
genesis, inactivation of MYC leads to loss of the malignant 
phenotype as a result of apoptotic cell death or differentia-
tion/senescence (Arvanitis and Felsher, 2006). To examine 
the fate of T-ALL cells in rag2:MYC-ER zebrafish after 4HT 
withdrawal, we monitored EGFP expression driven by the lck 
promoter, which is expressed in both immature and mature   
T cells, and dsRed2 expression driven by the rag2 pro-
moter, which is expressed in immature but not mature T cells 
(Langenau et al., 2004, 2005a). The loss of tumor cells after 
removal from 4HT did not appear to predominantly repre-
sent T cell differentiation because in each fish with tumor 
regression we noted the simultaneous disappearance of dis-
seminated cells expressing both EGFP and dsRed2 fluores-
cence, with no visible residual extrathymic EGFP-positive 
Figure 2.  T-ALL regression after MYC down-regulation occurs via 
mitochondrial apoptosis. (A) Immunohistochemical staining for the 
apoptotic marker activated caspase 3 was performed in rag2:MYC-ER 
transgenic zebrafish with T-ALL in the presence of 4HT (+4HT) and 4 d 
after 4HT removal (4HT). Number of fish analyzed = 4 per condition. 
Bars, 10 µm. (B) One representative rag2:MYC-ER; rag2:EGFP-bcl2; rag2:
dsRed2 triple-transgenic zebrafish is shown at the time of T-ALL onset 
and 3 wk after removal from 4HT. Bar, 1 mm. (C) Quantitation of T-ALL 
phenotypes 8 wk after MYC-ER inactivation, comparing rag2:EGFP-bcl2 
transgenic zebrafish versus rag2:dsRed2 controls. Number of fish ana-
lyzed per condition: rag2:MYC-ER;rag2:dsRed2, n = 12; rag2:MYC-ER; 
rag2:dsRed2; rag2:EGFP-bcl2, n = 20.1598 Pten mediates MYC oncogene dependence in T-ALL | Gutierrez et al.
failed to regress after MYC down-regulation (Fig. 2, B and C; P 
< 0.0001). Collectively, these findings implicate mitochon-
drial apoptosis as a central mediator of T-ALL regression after 
MYC down-regulation in this model.
Pten inactivating mutations promote loss of MYC  
oncogene dependence
We have recently identified genetic alterations of PTEN and 
the PI3K-AKT pathway in 48% of primary T-ALL human   
tumor specimens, most of which (86%) were also characterized 
by MYC overexpression (Gutierrez et al., 2009). We thus wanted 
to use our model to test the hypothesis that such alterations 
would render T-ALLs independent of MYC oncogenic activity 
for tumor maintenance. Because of a partial genome duplica-
tion event during teleost evolution, zebrafish have duplicated 
pten genes, known as ptenA and ptenB, both of which are 
highly conserved with mammalian PTEN genes, demonstrate 
phosphatase activity toward phosphatidylinositol(3,4,5)tri-
phosphate, and have redundant roles during zebrafish devel-
opment (Faucherre et al., 2008). Complete deficiency of all 
zebrafish  pten  alleles  leads  to  embryonic  lethality,  whereas 
compound haploinsufficiency is compatible with normal de-
velopment. To test whether pten is a modulator of MYC onco-
gene dependence, double-transgenic rag2:MYC-ER;rag2:GFP 
zebrafish were mated to fish harboring loss-of-function muta-
tions in their ptenA and/or ptenB genes (Fig. 3 A). Offspring 
from these matings were raised in 50 µg/liter (129 nM) 4HT 
beginning at 5 d postfertilization, the time at which thymic 
fluorescence is first visible in rag2:GFP transgenic fish, and   
T-ALL onset was monitored by weekly GFP fluorescence imag-
ing beginning at 4 wk of age. After development of disseminated 
T-ALL, fish were removed from 4HT to down-regulate MYC 
activity, and tumor phenotypes after 4HT removal were as-
sessed based on the degree of change in tumor   
size by the end of the 8-wk monitoring pe-
riod, as described in the previous section.
that mitochondrial (intrinsic) apoptosis might be the key 
mediator of T-ALL regression after MYC down-regulation, a 
hypothesis which we tested using a rag2:EGFP-bcl2 transgene, 
which blocks intrinsic apoptosis in thymocytes by binding 
and sequestering proapoptotic BCL2 family proteins (Langenau 
et al., 2005b). Indeed, we found that T-ALL tumors induced 
in rag2:MYC-ER zebrafish that also expressed rag2:EGFP-bcl2  
Figure 3.  pten haploinsufficiency does not accelerate onset of 
MYC-induced T-ALL. (A) Experimental design to test the effect of pten 
haploinsufficiency on T-ALL onset upon MYC-ER activation and on tumor 
regression after 4HT removal. (B) Analysis of T-ALL onset in zebrafish from 
the experiment described in A. Number of fish analyzed per genotype: 
ptenA +/+, ptenB +/+, n = 39; ptenA +/, ptenB +/+, n = 22; ptenA +/+, 
ptenB +/, n = 12; ptenA +/, ptenB +/, n = 10.
Figure 4.  pten haploinsufficiency promotes loss 
of MYC transgene dependence. (A and C) One repre-
sentative rag2:MYC-ER; rag2:GFP double-transgenic 
pten–wild-type zebrafish, shown at time of T-ALL 
onset (A) and 3 wk after removal from 4HT (C).  
(B and D) Representative rag2:MYC-ER; rag2:GFP double-
transgenic zebrafish that harbored heterozygous mu-
tations of both ptenA and ptenB, shown at time of 
T-ALL onset (B) and 3 wk after removal from 4HT  
(D). Bar, 1 mm. (E) Quantitation of T-ALL phenotypes 
after 4HT removal, based on pten genotype. Number of 
fish with T-ALL analyzed per genotype: ptenA +/+, 
ptenB +/+, n = 39; ptenA +/+, ptenB +/, n = 12; 
ptenA +/, ptenB +/+, n = 22; ptenA +/, ptenB +/, 
n = 10. (F) Western blot analysis for phosphorylation of 
S6 ribosomal protein, a marker of Akt pathway activa-
tion, in sorted T-ALL cells from five different rag2:
MYC-ER pten–wild-type zebrafish in which T-ALL pro-
gressed despite MYC down-regulation. Units for the 
molecular mass markers shown are in kD.JEM Vol. 208, No. 8 
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dependence (Fig. 5, B and C), suggesting that the effect of pten 
inactivation is mediated by Akt. T-ALLs arising in rag2:MYC-ER 
transgenic zebrafish expressing both rag2:myr-mAkt2 and 
rag2:GFP showing a complete or partial regression rate of 
14% after MYC-ER inhibition, compared with a regression rate 
of 75% in rag2:MYC-ER controls injected with rag2:GFP 
alone. Concomitantly, tumor progression rates were 86% in 
rag2:myr-mAkt2–injected  zebrafish,  compared  with  17%  of 
rag2:GFP-injected controls (Fig. 5 D; P = 0.0002 by 2 × 4 
Fisher’s exact test).
Akt pathway activation does not alter the transcriptional 
activity of Myc
Activated Akt  directly  phosphorylates  and  inhibits  GSK3 
(Cross et al., 1995), which is a key regulator of Myc protein 
stability (Sears et al., 2000), thus we wanted to test whether 
Akt pathway activation might substitute for MYC transgene 
activation by inducing the transcriptional activity of endoge-
nous Myc. The Ddx18 RNA helicase is a well established direct 
target of Myc in human and mouse cells (Grandori et al., 
1996; O’Hagan et al., 2000), and we used injection of Myc 
mRNA into zebrafish embryos followed by ddx18 RNA in situ 
Loss of up to two of the four zebrafish pten alleles did not 
measurably  accelerate  the  onset  of  MYC-induced T-ALL 
(Fig. 3 B); however, pten haploinsufficiency significantly pro-
moted loss of tumor dependence on MYC transgene activa-
tion (Fig. 4). The rates of complete or partial regression were 
69%  in  pten  wild-type  zebrafish,  58%  in  fish  harboring   
heterozygous ptenB mutations, 18% in fish harboring hetero-
zygous ptenA mutations, and 10% in pten double-heterozygous 
zebrafish (Fig. 4 E). Conversely, deficiency of pten also signifi-
cantly promoted tumor progression after MYC-ER inhibi-
tion, with progression rates of 13% in pten wild-type zebrafish, 
33 and 36% in fish harboring a single heterozygous mutation 
of ptenB or ptenA, respectively, and 60% in zebrafish harboring 
heterozygous mutations in both ptenA and ptenB (Fig. 4 E;   
P = 0.001 by 4 × 4 Fisher’s exact test). Thus, pten haploinsuffi-
ciency strongly promoted the loss of MYC transgene depen-
dence. Furthermore, Western blot analysis of the minority of 
T-ALL tumors from rag2:MYC-ER pten–wild-type zebrafish 
that progressed despite MYC down-regulation revealed that a 
subset of these tumors spontaneously acquired activation of 
the AKT pathway, as indicated by robust phosphorylation of 
S6 ribosomal protein (Fig. 4 F).
Constitutive Akt activation promotes loss of MYC  
oncogene dependence
Although PTEN is best known as a negative regulator of onco-
genic signaling through the PI3K–AKT pathway, evidence 
also suggests that PTEN has AKT-independent functions, in-
cluding regulation of p53 activity, chromosomal stability, and 
activity of the anaphase-promoting complex (Freeman et al., 
2003; Shen et al., 2007; Song et al., 2011). To test whether pten 
deficiency modulates MYC dependence via Akt pathway 
activation, we tested whether expression of rag2:myr-mAkt2, 
encoding a myristoylated constitutively active mouse Akt2 
transgene (Tan et al., 2008), would phenocopy the effect of 
pten inactivation on MYC transgene dependence. Hetero-
zygous rag2:MYC-ER zebrafish that did not harbor a thymic 
fluorescent transgene were out-crossed to wild-type animals, 
and all resultant embryos were injected at the one-cell stage 
with DNA expression constructs encoding rag2:GFP alone 
or  both  rag2:GFP  and  rag2:myr-mAkt2.  Injected  fish  were 
raised in 4HT to induce T-ALL, after which 4HT was re-
moved and tumor regression was monitored as in the pre-
vious section. Expression of rag2:myr-mAkt2 significantly 
accelerated the onset of T-ALL in rag2:MYC-ER transgenic 
zebrafish, with a mean age at T-ALL onset of 4.3 wk in rag2:
myr-mAkt2–injected fish, compared with 12.1 wk in control 
MYC-ER fish injected with rag2:GFP alone (Fig. 5 A; P = 
0.017). Expression of rag2:myr-mAkt2 in MYC-ER–negative 
zebrafish also induced T-ALL development in 17% of these 
fish by 20 wk (Fig. 5 A), indicating that Akt activation is suffi-
cient to induce T-ALL in the zebrafish, albeit at a relatively 
low penetrance.
Analysis of T-ALL regression after 4HT removal demon-
strated that expression of the constitutively active myr-mAkt2 
transgene was strongly associated with loss of MYC transgene 
Figure 5.  Constitutive Akt activation accelerates MYC-induced 
T-ALL and promotes loss of MYC transgene dependence. Germline 
rag2:MYC-ER heterozygous transgenic zebrafish were mated to wild-type 
fish, and all resultant offspring were injected at the one-cell stage with 
both rag2:GFP and rag2:myr-mAkt2 (15 pg of each DNA construct) or 
with rag2:GFP alone (30 pg). (A) Kaplan-Meier analysis of leukemia-free 
survival based on genotype. Number of GFP-fluorescent fish analyzed per 
genotype: rag2:MYC-ER negative, rag2:myr-mAkt2 negative, n = 10; 
rag2:MYC-ER negative, rag2:myr-mAkt2 positive; n = 18. rag2:MYC-ER 
positive, rag2:myr-mAkt2 negative, n = 12; rag2:MYC-ER positive,  
rag2:myr-mAkt2 positive, n = 21. (B) Representative rag2:MYC-ER germ-
line transgenic zebrafish injected with rag2:myr-mAkt2 and rag2:GFP, 
shown at the time of T-ALL onset and 3 wk after removal from 4HT. Bar,  
1 mm. (C) Quantitation of T-ALL phenotypes in rag2:MYC-ER–positive fish 
after 4HT removal, based on Akt genotype. Number of fish examined per 
group: rag2:myr-mAkt2, n = 21; rag2:GFP controls, n = 12.1600 Pten mediates MYC oncogene dependence in T-ALL | Gutierrez et al.
Myc represses Pten
The striking effect of pten haploinsufficiency on T-ALL re-
gression after MYC down-regulation contrasted sharply with 
the absence of a detectable phenotype of pten haploinsufficiency 
on onset of MYC-induced T-ALL. We wondered whether 
T-ALLs arising in a pten-haploinsufficient background might 
have an increased propensity to loss of wild-type pten alleles, 
but sequencing of ptenA and ptenB cDNAs generated from 
T-ALL cells sorted at the time of tumor onset in pten wild-type 
and pten double-heterozygous fish (n = 6 tumors from each 
genotype) revealed no mutational inactivation of wild-type 
alleles in any of the tumors analyzed.
We reasoned that MYC-induced repression of pten might 
explain the lack of a phenotype induced by pten haploinsuffi-
ciency in the setting of high MYC activity, whereas a striking 
phenotype might be expected after MYC inactivation if this 
led to the relief of pten repression. We thus measured ptenA 
and ptenB mRNA levels by Q-RT-PCR in sorted T-ALL 
cells from rag2:MYC-ER;rag2:EGFP-bcl2 transgenic zebrafish 
before and after 4HT removal. Q-RT-PCR analysis revealed 
that MYC down-regulation leads to a significant increase in 
transcript  levels  for  both  ptenA  and  ptenB,  indicating  that 
MYC represses pten, which is consistent with recent findings 
in mammalian cells (Mu et al., 2009; Olive et al., 2009; Kim 
et al., 2010; Mavrakis et al., 2010).
DISCUSSION
We have demonstrated for the first time that pten is an im-
portant mediator of MYC oncogene dependence in T-ALL 
lymphoblasts, an effect which appears to be mediated by its 
role as an inhibitor of oncogenic signaling through the Akt 
pathway. Furthermore, we also find that Myc represses Pten 
mRNA levels, an effect which is likely mediated by Myc- 
induced micro-RNAs which have recently been shown to 
down-regulate Pten (Mu et al., 2009; Olive et al., 2009; 
Kim et al., 2010; Mavrakis et al., 2010). Our data thus support 
a model in which Myc dependence is mediated in part by 
the up-regulation of Pten that follows Myc inactivation, 
which then acts to inhibit AKT pathway signaling which 
would otherwise be sufficient to maintain the malignant   
hybridization to confirm that the regulation of ddx18 by Myc 
is conserved in the zebrafish (Fig. 6 A). We then performed 
quantitative (Q) RT-PCR analysis of ddx18 mRNA levels 
in  sorted T-ALL  cells  from  rag2:MYC-ER;rag2:EGFP-bcl2 
zebrafish that also expressed either a rag2:GFP or a rag2:myr-
mAkt2 transgene. T-ALL cells were sorted from zebrafish in 
4HT and 4 d after 4HT removal. Expression of bcl2 was in-
cluded in all conditions to avoid the confounding effects of 
apoptosis induction after MYC down-regulation in the ab-
sence of myr-mAkt2 expression. Analysis of the transcrip-
tional  activity  of  Myc,  as  assessed  by  ddx18  Q-RT-PCR, 
revealed that it is regulated by 4HT treatment in rag2:MYC-
ER–positive T-ALL cells, whereas the overexpression of con-
stitutively active Akt had no effect on Myc transcriptional 
activity in the presence or absence of 4HT (Fig. 6 B). These 
findings were confirmed by Q-RT-PCR analysis for npm1a,   
a zebrafish orthologue of NPM1, another direct target of MYC 
(Zeller et al., 2001; Fig. S4). Collectively, these data indicate 
that the effect of Akt activation on Myc oncogene depen-
dence is not mediated by increasing the transcriptional activ-
ity of endogenous Myc.
Figure 6.  Expression of activated Akt does not alter the transcrip-
tional activity of MYC. (A) Whole mount RNA in situ hybridization for 
ddx18, a known direct target of MYC in mammalian cells (Grandori et al., 
1996; O’Hagan et al., 2000), performed at the 24-h postfertilization  
developmental stage in zebrafish embryos that were injected with 100 pg 
mCherry (control) or Myc mRNA at the one-cell stage. One representative 
zebrafish is shown in each condition out of a minimum of 20 embryos ana-
lyzed per condition. (B) Q-RT-PCR for ddx18 expression, performed using 
RNA from T-ALL cells from rag2:MYC-ER;rag2:EGFP-bcl2 zebrafish which 
also expressed either a rag2:GFP or a rag2:myr-mAkt2 transgene.  
T-ALL cells were sorted from animals in 4HT (+4HT) or 4 d after 4HT removal 
(4HT). -Actin was used as the Q-RT-PCR control. Bcl2-transgenic  
T-ALL cells were used in all conditions to avoid comparing live versus dying 
cells after MYC-ER inactivation. Error bars represent standard error of the 
mean. Number of tumors analyzed per group: 4HT+, myr-mAkt2, n = 6; 
4HT, myr-mAkt2, n = 7; 4HT+, myr-mAkt2+, n = 5; 4HT,  
myr-mAkt2+, n = 5.
Figure 7.  MYC represses pten. (A) Q-RT-PCR for ptenA and ptenB 
mRNA in T-ALL cells isolated from rag2:MYC-ER; rag2:EGFP-bcl2 trans-
genic zebrafish before and 4 d after 4HT removal, demonstrated that both 
zebrafish pten transcripts are repressed by MYC. -Actin was used as the 
Q-RT-PCR control. Error bars represent standard error of the mean. Num-
ber of tumors analyzed per condition: 4HT+, n = 6; 4HT, n = 7.  
(B) Model to explain our findings.JEM Vol. 208, No. 8 
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GFP fluorescence were examined for T-ALL development, and successful 
rag2:myr-mAkt2 transgene integration was verified by PCR at the end of 
each experiment.
4HT  treatment  and T-ALL  monitoring. Treatment  with  4HT  was   
begun starting at 5 d postfertilization, with each clutch placed in 750 ml of 
water containing 50 µg/liter (129 nM) 4HT (Sigma-Aldrich) in ethanol. 
Treatment with 4HT was performed offline, with weekly water changes 
beginning at 4 wk of age. Zebrafish raised in 4HT were screened for tumors 
by fluorescence microscopy weekly beginning at 4 wk of age. At the time of 
T-ALL onset and weekly during tumor regression monitoring, fish were 
imaged in both brightfield and GFP or dsRed2 fluorescent channels, as 
appropriate. Fluorescence microscopy was performed with a microscope 
(SMZ1500; Nikon) and an X-Cite 120 Fluorescence Illumination System 
(EXFO). Images were captured using a camera (DS2MBWc; Nikon) and 
NIS-Elements F Package (version 3.00; Nikon). All images shown represent 
merged fluorescence (shown in green or red, depending on the fluorophore) 
and brightfield (shown in grayscale) images. Fluorescence and brightfield 
images were merged using Photoshop (7.0; Adobe). Onset of T-ALL was 
defined as the development of a fluorescent mass arising from the thymus 
that was more than twice the size of normal thymus, together with invasion 
of adjacent tissues and structures. Note that we use T-ALL herein to refer to 
localized or disseminated T cell lymphoblastic tumors.
To monitor tumor regression, zebrafish with T-ALL were removed from 
4HT and placed in individual tanks online, and tumors were imaged weekly 
for a total of 8 wk. Tumor phenotypes after 4HT removal were categorized 
into four classes based on the change in the diameter of the largest contiguous 
tumor mass by the end of the 8-wk monitoring period, as described in the   
Results section. Fish that became moribund with leukemia <8 wk after tamox-
ifen were euthanized and classified into the progression category. Genotyping 
for rag2:MYC-ER, as well as ptenA and ptenB or rag2:myr-mAkt2, was performed 
by genomic PCR after the completion of each experiment. PCR genotyp-
ing primers were as follows: rag2:MYC-ER forward, 5-AGTCCTGAGA-
CAGATCAGCA-3, and reverse, 5-TCATCATGCGGAACCGACTT-3; 
and  rag2:myr-mAkt2  forward,  5-ATGCTAATTTGAAGCACTAGCA-3, 
and reverse, 5-TTGGGTCCTTCTTCAGCAGT-3. Genotyping for ptenA 
and ptenB was performed as previously described (Faucherre et al., 2008).
Zebrafish paraffin sectioning and immunohistochemistry. Zebrafish 
were euthanized in tricaine anesthetic, fixed in 4% paraformaldehyde at 4°C 
for 2 d, decalcified with 0.25 M EDTA, pH 8.0, for 2 d, dehydrated in alcohol, 
cleared in xylene, and embedded in paraffin. Slides were deparaffinized and 
pretreated with 10 mM citrate, pH 6.0, in a steam pressure cooker (Decloaking 
Chamber; BioCare Medical) according to the manufacturer’s instructions, fol-
lowed by washing in distilled water. Slides were pretreated with Peroxidase 
Block (Dako) for 5 min, followed by serum-free protein block (Dako) for 20 min 
to block nonspecific binding sites. Slides were then incubated with primary 
rabbit anticleaved caspase-3 antibody (1:50; Cell Signaling Technology) or 
mouse anti-GFP antibody (1:1500; Takara Bio Inc.). Secondary detection was 
performed by adding horseradish peroxidase-labeled polymer (Dako) for 
30 min. Immunoperoxidase staining was developed with diaminobenzidine + 
chromogen kit (Dako), according to the manufacturer’s instructions.
Zebrafish  cryosectioning  and  -galactosidase  staining.  Zebrafish 
were euthanized in tricaine anesthetic, embedded in a 1:1 mixture of 30% 
sucrose and Tissue-Tek O.C.T. compound (Sakura), and snap-frozen in iso-
butane precooled in dry ice. 14-µm frozen sections were cut onto slides using 
a CM3050 cryostat (Leica). Staining for activity of senescence-associated 
-galactosidase was performed using the Senescence -Galactosidase Staining 
kit (Cell Signaling Technology) according to the manufacturer’s instructions.
Western blotting. DsRed2-sorted T-ALL cells were lysed in RIPA buffer 
(Millipore) supplemented with Complete Mini protease inhibitor (1 tablet/ 
10 ml; Roche) and PhosSTOP phosphatase inhibitor (1 tablet/10 ml; 
Roche). 20 µg protein lysate was mixed with Laemmli 4× SDS sample buffer 
(Boston Bioproducts) and -mercaptoethanol (Sigma-Aldrich) in appropriate 
phenotype, even in the absence of oncogenic signals mediated 
by Myc (Fig. 7 B).
Our findings implicate apoptotic cell death through the 
mitochondrial pathway as a critical mediator of Myc onco-
gene dependence in this model, thus indicating that inhibi-
tion of apoptosis downstream of AKT is the likely mechanism 
through which Pten haploinsufficiency induces loss of Myc 
oncogene dependence. Akt has previously been shown to in-
hibit mitochondrial apoptosis via multiple pathways (Manning 
and Cantley, 2007), including inactivation of BAD via phos-
phorylation (Datta et al., 1997; del Peso et al., 1997), tran-
scriptional down-regulation of BIM downstream of its effect 
on FOXO proteins (Dijkers et al., 2002), inhibition of p53 via 
phosphorylation and activation of MDM2 (Mayo and Donner, 
2001; Zhou et al., 2001), and up-regulation of the antiapop-
totic MCL1 downstream of both mTOR (Wei et al., 2006; 
Hsieh et al., 2010) and GSK3 (Maurer et al., 2006). Our re-
sults indicate that AKT activation is one mechanism that can 
overcome MYC oncogene dependence in T-ALL, suggesting 
that PI3K-AKT inhibitors may have therapeutic utility in 
combination with inhibitors of MYC itself in the design of 
new therapeutic strategies for T-ALL.
MATERIALS AND METHODS
Transgenic and mutant zebrafish lines. The rag2:MYC-ER construct 
was generated by placing a human MYC transgene fused to the ligand-binding 
domain of the estrogen receptor, which is posttranslationally induced by 
4HT but not endogenous estrogens (Littlewood et al., 1995), downstream of 
the zebrafish rag2 promoter in a modified pBluescript vector in which the 
rag2:MYC-ER construct is flanked by recognition sequences for I-SceI 
meganuclease. This circular rag2:MYC-ER was co-injected together with a 
wild-type mitfa construct under its own promoter, also flanked by I-SceI rec-
ognition sequences, into one-cell stage embryos from the nacre line using a 
previously described I-SceI co-injection strategy (Grabher and Wittbrodt, 
2008). Nacre zebrafish harbor a pigmentation defect caused by homozygous 
germline mitfa loss-of-function mutations, thus allowing rescue of the pig-
mentation defect by the co-injected mitfa transgene to act as a trans-genesis 
marker. A line derived from one rag2:MYC-ER;mitf founder zebrafish was 
identified that developed 4HT-dependent T-ALL and was used for all further 
studies. Co-segregation of the rag2:MYC-ER transgene together with the 
pigment-rescue phenotype was confirmed by PCR in all subsequent genera-
tions using the PCR primers described in the next section.
The  lck:EGFP,  rag2:GFP,  rag2:EGFP-bcl2,  and  fli1:EGFP  transgenic   
zebrafish lines have previously been described (Lawson and Weinstein, 2002; 
Langenau et al., 2003, 2004, 2005b). The transgenic line referred to here as 
rag2:dsRed2  harbors  a  rag2:LoxP-dsRed2-STOP-LoxP-EGFP-mMyc  trans-
gene, which in the absence of Cre demonstrates dsRed2 expression driven by 
the rag2 promoter (Langenau et al., 2005a). It is worth noting that zebrafish 
expressing this construct demonstrate no detectable EGFP-Myc translation 
in the absence of Cre, as indicated by the absence of detectable EGFP fluo-
rescence or spontaneous T-ALL development and by the lack of modification 
of T-ALL onset or regression in the rag2:MYC-ER line. Zebrafish harboring 
loss-of-function mutations in ptenA and ptenB genes were previously de-
scribed (Faucherre et al., 2008).
The rag2:myr-mAkt2 construct was generated by placing a myristoylated 
mouse Akt2 transgene (Tan et al., 2008), which is constitutively activated as a 
result of constitutive membrane localization, downstream of the rag2 pro-
moter in the I-SceI–modified pBluescript vector described in the first para-
graph  in  this  section.  Microinjections  of  the  rag2:myr-mAkt2  expression 
construct together with rag2:GFP (15 pg per embryo of each), or of rag2:
GFP alone as a control (30 pg per embryo), were performed as previously 
described (Grabher and Wittbrodt, 2008). Zebrafish demonstrating thymic 1602 Pten mediates MYC oncogene dependence in T-ALL | Gutierrez et al.
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